Aspira Women's Health Board Changes

Ticker: AWHL · Form: 8-K · Filed: Jun 27, 2024 · CIK: 926617

Aspira Women'S Health INC. 8-K Filing Summary
FieldDetail
CompanyAspira Women'S Health INC. (AWHL)
Form Type8-K
Filed DateJun 27, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: board-changes, executive-compensation

TL;DR

Aspira Women's Health swapped a director and updated executive pay on 6/27.

AI Summary

Aspira Women's Health Inc. announced on June 27, 2024, a change in its board of directors. Specifically, the company reported the departure of Director Dr. Michael J. McNeely and the election of Dr. David L. Smith as a new Class III director. The company also disclosed compensatory arrangements for certain officers.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — This filing primarily concerns routine board and officer changes and compensatory arrangements, which are common corporate events.

Key Players & Entities

FAQ

Who has been elected as a new Class III director for Aspira Women's Health Inc.?

Dr. David L. Smith has been elected as a new Class III director.

Which director has departed from Aspira Women's Health Inc.'s board?

Dr. Michael J. McNeely has departed from the board.

What is the exact date of the report for these changes?

The date of the report is June 27, 2024.

What other item is Aspira Women's Health Inc. reporting in this 8-K filing besides director changes?

The company is also reporting on compensatory arrangements of certain officers.

What is the state of incorporation for Aspira Women's Health Inc.?

The state of incorporation is Delaware.

Filing Stats: 757 words · 3 min read · ~3 pages · Grade level 12.1 · Accepted 2024-06-27 17:21:52

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASPIRA WOMEN'S HEALTH INC. Date: June 27, 2024 By: /s/ Nicole Sandford Nicole Sandford Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing